You are now visiting tipharma.com.
On 1 January, 2016, TI Pharma and CTMM merged
to form a new organization called Lygature.
Please note that information on the tipharma.com site has not
been updated since, and is retained as an archive.
For up-to-date information, please visit lygature.org.
The TI Pharma governance consists of a Board of Directors, a Management Team and an International Scientific Review Committee. In addition, an annual meeting is organized for representatives of all TI Pharma stakeholders.
Board of Directors
The Board of Directors is a non-executive Board which consists of 5 to 9 members drawn from the various "blood groups" that make up TI Pharma: global pharmaceutical companies, small and medium sized enterprises and clinical and preclinical academic researchers. Members of the Board of Directors act in a personal capacity. The role of the board is to appoint the Management Team and decide on strategy, approve the annual budget, monitor project progress and, if applicable, decide on funding of projects.
The Management Team (MT) is responsible for the day-to-day management of the Institute, drafting the institutes strategy, monitoring the progress and (scientific) quality of projects, acquiring new projects, partners and funding, and prepares the meetings of the Board of Directors.
An independent committee, the International Scientific Review Committee (ISRC), serves as advisor to the Board of Directors and the Management Team. The ISRC is responsible for a (bi-) annual review of the institute. It assesses the balance in the overall project portfolio and overall quality, and performs an independent check on how TI Pharma is meeting its strategic objectives.
“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”
Director/Secretary of the Medicines Evaluation Board